Seattle Genetics and Takeda Complete Enrollment of Phase 3 ECHELON-2...

Seattle Genetics and Takeda Complete Enrollment of Phase 3 ECHELON-2...

Seattle Genetics and Takeda Complete Enrollment of Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS A in Frontline Mature T-cell Lymphoma -ECHELON-2 Trial Represents Key Component of Late-Stage Clinical Development Strategy to Establish ADCETRIS as Foundation of Care for CD30-Expressing Lymphomas- )-- Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited today announced completion of patient enrollment in the ECHELON-2 clinical trial. ECHELON-2 is a global phase 3 randomized trial evaluating ADCETRIS as part of a frontline combination chemotherapy regimen in patients with previously untreated CD30-positive mature T-cell lymphoma .

from Biotech News